News
Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...
This was the stock's fourth consecutive day of gains.
Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.
The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...
RFK Jr. cancels U.S. Preventive Services Task Force meeting; the Department of Health and Human Services backtracked on its claim that it would release ethics forms for new members of the Advisory ...
On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...
DekaBank Deutsche Girozentrale increased its stake in Regeneron Pharmaceuticals by 4.7% this quarter, now holding 221,176 ...
Valley Stream South High School alums call for reinstatement of science research advisor Jeffrey Hsi
Jeffrey Hsi, a longtime physics teacher at South High School in the Valley Stream Central High School District, has been ...
A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...
A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...
Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.
Following updates by the CDC’s Advisory Committee on Immunization Practices, a coalition of pharmacy organizations has urged insurers to continue to cover vaccines unless there is “clear evidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results